Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1999 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Recurrent Uterine Corpus Leiomyosarcoma"
Page 1
Major clinical research advances in gynecologic cancer in 2015.
Suh DH, Kim M, Kim HJ, Lee KH, Kim JW. Suh DH, et al. J Gynecol Oncol. 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. J Gynecol Oncol. 2016. PMID: 27775259 Free PMC article. Review.
For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was reviewed. For corpus cancer, the safety concern of power morcellation in presumed fibroids was explored again with regard to age and preva …
For cervical cancer, update of human papillomavirus vaccines regarding two-dose regimen, 9-valent vaccine, and therapeutic vaccine was revie …
Hormone replacement therapy after uterine leiomyosarcoma treatment. Case reports.
Ursic-Vrscaj M. Ursic-Vrscaj M. Eur J Gynaecol Oncol. 1999;20(5-6):379-82. Eur J Gynaecol Oncol. 1999. PMID: 10609499
Uterine sarcomas are extremely rare uterine malignancies; with a review of the literature we could not find any data dealing with exogenous oestrogens or combined hormone replacement therapy (HRT) after leiomyosarcoma treatment. We report two cases of patient …
Uterine sarcomas are extremely rare uterine malignancies; with a review of the literature we could not find any data dealing w …
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. Omura GA, et al. J Clin Oncol. 1985 Sep;3(9):1240-5. doi: 10.1200/JCO.1985.3.9.1240. J Clin Oncol. 1985. PMID: 3897471 Clinical Trial.
After hysterectomy, 156 evaluable patients with stage I (limited to the corpus) or stage II (limited to the corpus and cervix) uterine sarcomas were randomly assigned to adjuvant chemotherapy with Adriamycin (Adria Laboratories, Columbus, Ohio) for six …
After hysterectomy, 156 evaluable patients with stage I (limited to the corpus) or stage II (limited to the corpus and cervix) …